AEON Biopharma(US:AEON)2026-03-30 21:29Financial Performance - AEON Biopharma reported cash and cash equivalents of $3.0 million as of December 31, 2025, which does not include $4.2 million from PIPE financing received in January 2026[13]. - The company strengthened its balance sheet through $6 million PIPE financing and a note exchange, reducing outstanding debt by more than 90%[5][10]. - AEON reported a net loss of $39.2 million for the year ended December 31, 2025, compared to a net income of $42.0 million in 2024[26]. - Total operating expenses for 2025 were $12.8 million, a decrease from $73.0 million in 2024[26]. - AEON's total assets increased to $5.6 million in 2025, up from $3.1 million in 2024[24]. Product Development - The primary structure of ABP-450 exhibited a 100% sequence match to BOTOX®, based on sequence coverage of 93–99% across all five proteins[6]. - AEON plans to complete the majority of its analytical comparability program in 2026, following positive initial comparative analytical results[7][16]. - The company aims to request a BPD Type 2b meeting in 2026 to discuss the next phase of the development program for ABP-450[16]. Market Opportunity - AEON's U.S. therapeutic neurotoxin market opportunity exceeds $3.0 billion annually, representing a significant potential for biosimilar entry[17]. Leadership Changes - The company appointed John Bencich as Chief Financial Officer in March 2026, bringing over 25 years of experience in corporate strategy and capital markets[11].